Sector News

Valeant said to step up talks on potential $800M deal for Egypt’s Amoun

June 18, 2015
Life sciences
Last month, reports said Valeant was eyeing up one of Egypt’s largest drugmakers. Now, word has it, those talks have progressed, and the Canadian pharma could be ready to pull the trigger in the coming weeks.
 
The serial buyer is in advanced negotiations to buy Amoun Pharmaceutical, Bloomberg reports, though no final decision has been made–meaning any deal could still fall apart. A sale could value the company between $700 million and $800 million, the news service’s sources said in May.
 
If Valeant were to grab Amoun, it would mark its third buyout of the year. After losing out on a months-long hostile takeover try for Allergan last November, the avid dealmaker has already snapped up North Carolina’s Salix–beating out rival bidder Endo–and the assets from bankrupt Seattle biotech Dendreon in the first half of 2015.
 
But unlike those transactions–which helped the company bulk up in GI and oncology, respectively–an Amoun tie-up would strengthen Valeant in fast-growing emerging markets. Beefing up in developing nations was one perk of the proposed Allergan merger, and a goal Pearson has already worked toward with deals like 2012’s for Mexican branded-generics company Atlantis Pharma.
 
It’s all part of Valeant’s strategy to expand through M&A in high-growth spaces–both geographic and therapeutic. Before the Salix and Dendreon deals, Valeant’s moves–like the Allergan play, and its 2013 pickup of Bausch + Lomb–were centered on skincare and eye care, two other hot fields Pearson had tabbed for expansion.
 
By Carly Helfand
 

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).